Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
10.08
-0.49 (-4.59%)
Oct 30, 2026, 12:48 PM EDT - Market open
Kura Oncology Revenue
Kura Oncology had revenue of $20.87M in the quarter ending June 30, 2026, with 36.54% growth. This brings the company's total for the last twelve months to $77.23M, down -7.27% year-over-year. In the year 2025, Kura Oncology had annual revenue of $67.48M with 25.24% growth. That makes Kura Oncology the 24,651st largest company in the world by revenue and 3,458th in the United States.
Revenue (ttm)
$77.23M
Revenue Growth
-7.27%
P/S Ratio
12.16
Revenue / Employee
$297,019
Employees
260
Market Cap
896.28M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.48M | 13.60M | 25.24% |
| Dec 31, 2024 | 53.88M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 397.50M |
| Rigel Pharmaceuticals | 276.79M |
| Ginkgo Bioworks Holdings | 132.42M |
| Monte Rosa Therapeutics | 28.73M |
| Aktis Oncology | 10.06M |
| Alumis | 7.40M |
| Prime Medicine | 4.07M |
| Odyssey Therapeutics | 99.00K |
KURA News
- 16 days ago - Kura Oncology Transcript: Investor update - Transcripts
- 16 days ago - Kura Oncology Press release: Investor update - Filings
- 16 days ago - Kura Oncology Slides: Investor update - Filings
- 17 days ago - Kura Oncology, Caspian outline KO-7246 development strategy in diabetes - TheFly
- 17 days ago - Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes - GlobeNewsWire
- 23 days ago - Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes - GlobeNewsWire
- 4 weeks ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Kura Oncology initiated with an Overweight at JPMorgan - TheFly